CN114624165A - 血液样本中中性粒细胞cd64的测定方法 - Google Patents
血液样本中中性粒细胞cd64的测定方法 Download PDFInfo
- Publication number
- CN114624165A CN114624165A CN202210237515.8A CN202210237515A CN114624165A CN 114624165 A CN114624165 A CN 114624165A CN 202210237515 A CN202210237515 A CN 202210237515A CN 114624165 A CN114624165 A CN 114624165A
- Authority
- CN
- China
- Prior art keywords
- antibody
- blood sample
- fluorescence intensity
- neutrophils
- neutrophil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 title claims abstract description 96
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 title claims abstract description 95
- 210000000440 neutrophil Anatomy 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 46
- 210000004369 blood Anatomy 0.000 title claims abstract description 44
- 239000008280 blood Substances 0.000 title claims abstract description 44
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 43
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 43
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 41
- 210000001616 monocyte Anatomy 0.000 claims abstract description 38
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract description 30
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract description 30
- 230000003287 optical effect Effects 0.000 claims abstract description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 30
- 238000011534 incubation Methods 0.000 claims description 15
- 239000003219 hemolytic agent Substances 0.000 claims description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 230000007717 exclusion Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 31
- 238000001514 detection method Methods 0.000 description 18
- 238000004364 calculation method Methods 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 208000035473 Communicable disease Diseases 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 5
- 201000006747 infectious mononucleosis Diseases 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000028315 developmental maturation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000011527 multiparameter analysis Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
- G01N2015/144—Imaging characterised by its optical setup
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210237515.8A CN114624165B (zh) | 2022-03-10 | 2022-03-10 | 血液样本中中性粒细胞cd64的测定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210237515.8A CN114624165B (zh) | 2022-03-10 | 2022-03-10 | 血液样本中中性粒细胞cd64的测定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114624165A true CN114624165A (zh) | 2022-06-14 |
CN114624165B CN114624165B (zh) | 2023-05-23 |
Family
ID=81902333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210237515.8A Active CN114624165B (zh) | 2022-03-10 | 2022-03-10 | 血液样本中中性粒细胞cd64的测定方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114624165B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0627017A (ja) * | 1992-01-22 | 1994-02-04 | Becton Dickinson & Co | 多元的細胞識別分析法 |
CN101389959A (zh) * | 2005-11-04 | 2009-03-18 | 贝克曼考尔特公司 | 用于血癌分析与临床处理的细胞抗原及靶信号转导蛋白的复合分布 |
CN109655616A (zh) * | 2018-12-19 | 2019-04-19 | 广州金域医学检验中心有限公司 | 检测急性髓系白血病细胞的组合试剂及系统 |
CN110579595A (zh) * | 2019-09-10 | 2019-12-17 | 核工业总医院 | 一种等张溶血素及其制备方法、处理生物样本方法和检测白细胞膜抗原方法 |
CN110823789A (zh) * | 2019-11-28 | 2020-02-21 | 徐州市儿童医院 | 一种用于临床感染性疾病的中性粒细胞cd64测定方法 |
CN111551416A (zh) * | 2020-03-22 | 2020-08-18 | 华南理工大学 | 一种基于细胞膜磷脂酰丝氨酸荧光染色的细菌类凋亡评价方法 |
US20200405779A1 (en) * | 2018-02-28 | 2020-12-31 | The Johns Hopkins University | Bacterial biofilms and cancer |
CN113188982A (zh) * | 2021-04-30 | 2021-07-30 | 天津深析智能科技发展有限公司 | 淋巴细胞亚群自动分析中有效去除单核细胞干扰的方法 |
CN113419066A (zh) * | 2021-08-23 | 2021-09-21 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 一步法筛查和/或诊断克隆性疾病的试剂组合物及其应用 |
-
2022
- 2022-03-10 CN CN202210237515.8A patent/CN114624165B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0627017A (ja) * | 1992-01-22 | 1994-02-04 | Becton Dickinson & Co | 多元的細胞識別分析法 |
CN101389959A (zh) * | 2005-11-04 | 2009-03-18 | 贝克曼考尔特公司 | 用于血癌分析与临床处理的细胞抗原及靶信号转导蛋白的复合分布 |
US20200405779A1 (en) * | 2018-02-28 | 2020-12-31 | The Johns Hopkins University | Bacterial biofilms and cancer |
CN109655616A (zh) * | 2018-12-19 | 2019-04-19 | 广州金域医学检验中心有限公司 | 检测急性髓系白血病细胞的组合试剂及系统 |
CN110579595A (zh) * | 2019-09-10 | 2019-12-17 | 核工业总医院 | 一种等张溶血素及其制备方法、处理生物样本方法和检测白细胞膜抗原方法 |
CN110823789A (zh) * | 2019-11-28 | 2020-02-21 | 徐州市儿童医院 | 一种用于临床感染性疾病的中性粒细胞cd64测定方法 |
CN111551416A (zh) * | 2020-03-22 | 2020-08-18 | 华南理工大学 | 一种基于细胞膜磷脂酰丝氨酸荧光染色的细菌类凋亡评价方法 |
CN113188982A (zh) * | 2021-04-30 | 2021-07-30 | 天津深析智能科技发展有限公司 | 淋巴细胞亚群自动分析中有效去除单核细胞干扰的方法 |
CN113419066A (zh) * | 2021-08-23 | 2021-09-21 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 一步法筛查和/或诊断克隆性疾病的试剂组合物及其应用 |
Non-Patent Citations (6)
Title |
---|
DH FANG: "Ratios of CD64 expressed on neutrophils, monocytes, and lymphocytes may be a novel method for diagnosis of neonatal sepsis", 《THE JOURNAL OF INFECTION IN DEVELOPING CONTRIES》 * |
张小彬;陆云飞;李三;莫武宁;秦雪;: "流式细胞术分析乳腺癌前哨淋巴结淋巴细胞亚群的两种方法比较", 《广西医科大学学报》 * |
李蕊: "CD64在危重疾病合并感染诊断中的应用进展", 《临床检验杂志》 * |
王敏: "《医学免疫学实验指导》", 31 March 2016, 北京邮电大学出版社 * |
苏密龙;苏智军;余雪平;郭如意;黄绿叶;康斌;杨伟;: "流式细胞术检测单核细胞、中性粒细胞CD64临床价值研究", 《中国免疫学杂志》 * |
陈江等: "CD64感染指数与细菌感染相关性研究", 《检验医学与临床》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114624165B (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10222320B2 (en) | Identifying and enumerating early granulated cells (EGCs) | |
Boer et al. | Evaluation of the XE-5000 for the automated analysis of blood cells in cerebrospinal fluid | |
WO2016106688A1 (zh) | 一种有核红细胞报警方法、装置及流式细胞分析仪 | |
US5776709A (en) | Method for preparation and analysis of leukocytes in whole blood | |
WO2008046292A1 (fr) | Procédé d'analyse du sang en cinq étapes fondée sur une image visuelle | |
JPH0379666B2 (zh) | ||
JPH02103464A (ja) | サンプル中の損傷細胞及びインタクト細胞を識別するための方法 | |
JP4435948B2 (ja) | 白血球の分類計数方法 | |
US6159740A (en) | Method and apparatus for screening obscured or partially obscured cells | |
Koken et al. | Determination of cut-off values for leucocytes and bacteria for urine flow cytometer (UF-100) in urinary tract infections | |
CN110823789A (zh) | 一种用于临床感染性疾病的中性粒细胞cd64测定方法 | |
CN104749108B (zh) | 血中丝虫幼虫的检测方法、血液分析装置和信息处理系统 | |
CN114441419B (zh) | 流式圈门方法及应用 | |
EP0559208A1 (en) | Method for preparation and analysis of leukocytes in whole blood utilizing flow cytometry | |
CN114624165B (zh) | 血液样本中中性粒细胞cd64的测定方法 | |
CN111537735A (zh) | 抗体检测试剂盒以及在免疫分析方面的应用 | |
Harrison et al. | Platelet counting | |
AU5438890A (en) | Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics utilizing at least one sensing parameter | |
CN111504886B (zh) | 一组分子在制备新冠肺炎辅助诊断试剂或试剂盒中的应用 | |
EP3904495A1 (en) | Blood analysis device, computer program, and blood analysis method | |
Anchinmane et al. | Detection of malarial parasite in urine of malaria patients: a future diagnostic approach | |
JP6883826B2 (ja) | 骨髄異形成症候群の診断方法 | |
CN115327135A (zh) | 中性粒细胞cd64感染指数的测定试剂及其测定方法 | |
Zhou et al. | The progress in pre-transfusion test technique research | |
Merah‐Mourah et al. | A Two‐Stage Flow Cytometry Strategy to Distinguish Single Cells from Doublets in Heterogeneous Cell Mixtures and Improve Cell Cluster Identification: Application to Human Monocyte Subpopulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230728 Address after: 225300 East side of Tai Road at the entrance of China Pharmaceutical City, Taizhou Medical High tech Industrial Development Zone, Jiangsu Province, and west side of the first floor of Building G23, Building 0003, north side of Xinyang Road Patentee after: Jiangsu Lu's Biotechnology Co.,Ltd. Address before: 310051 room 1401, floor 14, building 5, No. 688, Bin'an Road, Changhe street, Binjiang District, Hangzhou, Zhejiang Province Patentee before: Hangzhou Xiangyu medical laboratory Co.,Ltd. |
|
TR01 | Transfer of patent right |